Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reduced ULK1 links impaired autophagy and mitophagy to Alzheimer's disease pathology.

Nature aging·2026
Same author

Changes in device-measured daily physical activity over one year in memory clinic patients.

European review of aging and physical activity : official journal of the European Group for Research into Elderly and Physical Activity·2026
Same author

Plasma p-tau217 and glucose metabolism correlate in neocortical association areas in Alzheimer's disease.

Brain communications·2026
Same author

Prognostic Added Value of GFAP in Patients With Minor Ischemic Stroke.

European journal of clinical investigation·2026
Same author

Diagnostic performance of plasma GFAP in preclinical stages of Alzheimer's disease using the Lumipulse platform.

Alzheimer's research & therapy·2026
Same author

Long-COVID: assessment of circulating markers suggests no cerebral neuronal damage, neuroinflammation or systemic inflammation-a controlled study.

Scientific reports·2026

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Anne-Brita Knapskog1, Guglielmo Di Molfetta2, Heidi Vihovde Sandvig3

  • 1Oslo University Hospital, Oslo, Norway.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 24, 2025
PubMed
Summary
This summary is machine-generated.

High levels of brain-derived tau (BD-tau), neurofilament light chain (NfL), and phosphorylated tau (p-tau181) in acute stroke plasma predict long-term cognitive decline. These biomarkers indicate a continuing neurodegenerative process post-stroke, impacting post-stroke cognitive impairment (PSCI).

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Area of Science:

  • Neuroscience
  • Neurology
  • Biomarker Research

Background:

  • Vascular risk factors increase Alzheimer's disease (AD) incidence, and AD patients have higher stroke risk.
  • Approximately 50% of stroke survivors experience post-stroke cognitive impairment (PSCI).
  • Stroke initiates inflammatory and neurodegenerative processes, necessitating investigation into predictive biomarkers for PSCI.

Purpose of the Study:

  • To analyze longitudinal plasma biomarker data in stroke patients.
  • To determine if baseline neurodegenerative and acute injury biomarkers predict PSCI.
  • To explore associations between plasma biomarkers and cognitive decline up to 36 months post-stroke.

Main Methods:

  • Included 547 stroke patients (89% ischemic) in the Nor-COAST substudy.
  • Measured plasma concentrations of BD-tau, p-tau181, t-tau, Aβ40, Aβ42, GFAP, and NfL using the Simoa platform at multiple time points.
  • Assessed cognitive function using the Montreal Cognitive Assessment (MoCA) scale up to 36 months post-stroke.

Main Results:

  • BD-tau, t-tau, and GFAP decreased within 3 months; NfL stabilized by 18 months; p-tau181 gradually increased.
  • Higher acute phase concentrations of BD-tau, NfL, and p-tau181 predicted lower MoCA scores up to 36 months in ischemic stroke patients.
  • Associations were attenuated by clinical parameters and not observed in hemorrhagic stroke patients.

Conclusions:

  • Plasma BD-tau, NfL, GFAP, and t-tau were elevated acutely post-stroke, with varying stabilization times.
  • Elevated acute BD-tau, NfL, and p-tau181 concentrations correlate with worse long-term cognitive outcomes.
  • Stroke triggers ongoing neurodegeneration, evidenced by increasing p-tau181, contributing to PSCI.